Simpson Thacher represented Certara, Inc. (“Certara”) and an entity affiliated with EQT AB (“EQT”) in connection with Certara’s initial public offering of common stock. A total of 33,413,250 shares of common stock were sold in the offering, consisting of 14,630,000 shares sold by Certara and 18,783,250 shares sold by EQT and the other selling stockholders, inclusive of the underwriters’ full exercise of their option to purchase additional shares. The offering raised approximately $768.5 million in gross proceeds. Shares of Certara, Inc. are now listed on The Nasdaq Global Select Market under the ticker symbol “CERT.”
Certara, a global leader in biosimulation based on 2019 revenue, accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries.
The Simpson Thacher team included Bill Brentani, Kelli Schultz, Jonathan Kachiu and Bori Celia Ha (Capital Markets); Michael T. Holick, Frederick W.P. De Albuquerque and Fiona S. Gillan (M&A); Jennifer Nadborny and Joia E. Lee (Public Company Advisory Practice); David Rubinsky, Jeannine McSweeney, Patricia Adams and J. Pasco Struhs (Executive Compensation and Employee Benefits); Eli Isak (Credit); Amber Harezlak (IP); Vanessa K. Burrows (Healthcare); Jonathan Goldstein, Jonathan Cantor, Jacqueline Clinton, Kelli Rivers and Jasmine N. Hay (Tax); and Jennie Getsin (FINRA).